The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Exosome CDMO Market Research Report 2024
Synopsis
The global Exosome CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Exosome CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Exosome CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Exosome CDMO in Laboratory is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Exosome CDMO include REPROCELL, Histocell, Lonza, CytoNiche, MYCENAX, RoosterBio, WuXi Advanced Therapies, Asahi Glass Co. and Fortis Life Sciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Exosome CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Exosome CDMO.
Report Scope
The Exosome CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Exosome CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Exosome CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
REPROCELL
Histocell
Lonza
CytoNiche
MYCENAX
RoosterBio
WuXi Advanced Therapies
Asahi Glass Co.
Fortis Life Sciences
Scorpius BioManufacturing
Miltenyi Bioindustry
AGC Biologics
Exothera
Segment by Type
Preclinical CRO
Clinical CRO
Segment by Application
Laboratory
Universities
Bio Industry
Medical Industry
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Exosome CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Exosome CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Exosome CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Exosome CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Exosome CDMO in Laboratory is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Exosome CDMO include REPROCELL, Histocell, Lonza, CytoNiche, MYCENAX, RoosterBio, WuXi Advanced Therapies, Asahi Glass Co. and Fortis Life Sciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Exosome CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Exosome CDMO.
Report Scope
The Exosome CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Exosome CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Exosome CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
REPROCELL
Histocell
Lonza
CytoNiche
MYCENAX
RoosterBio
WuXi Advanced Therapies
Asahi Glass Co.
Fortis Life Sciences
Scorpius BioManufacturing
Miltenyi Bioindustry
AGC Biologics
Exothera
Segment by Type
Preclinical CRO
Clinical CRO
Segment by Application
Laboratory
Universities
Bio Industry
Medical Industry
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Exosome CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Exosome CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Preclinical CRO
1.2.3 Clinical CRO
1.3 Market by Application
1.3.1 Global Exosome CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Laboratory
1.3.3 Universities
1.3.4 Bio Industry
1.3.5 Medical Industry
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Exosome CDMO Market Perspective (2019-2030)
2.2 Exosome CDMO Growth Trends by Region
2.2.1 Global Exosome CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Exosome CDMO Historic Market Size by Region (2019-2024)
2.2.3 Exosome CDMO Forecasted Market Size by Region (2025-2030)
2.3 Exosome CDMO Market Dynamics
2.3.1 Exosome CDMO Industry Trends
2.3.2 Exosome CDMO Market Drivers
2.3.3 Exosome CDMO Market Challenges
2.3.4 Exosome CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Exosome CDMO Players by Revenue
3.1.1 Global Top Exosome CDMO Players by Revenue (2019-2024)
3.1.2 Global Exosome CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Exosome CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Exosome CDMO Revenue
3.4 Global Exosome CDMO Market Concentration Ratio
3.4.1 Global Exosome CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Exosome CDMO Revenue in 2023
3.5 Exosome CDMO Key Players Head office and Area Served
3.6 Key Players Exosome CDMO Product Solution and Service
3.7 Date of Enter into Exosome CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Exosome CDMO Breakdown Data by Type
4.1 Global Exosome CDMO Historic Market Size by Type (2019-2024)
4.2 Global Exosome CDMO Forecasted Market Size by Type (2025-2030)
5 Exosome CDMO Breakdown Data by Application
5.1 Global Exosome CDMO Historic Market Size by Application (2019-2024)
5.2 Global Exosome CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Exosome CDMO Market Size (2019-2030)
6.2 North America Exosome CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Exosome CDMO Market Size by Country (2019-2024)
6.4 North America Exosome CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Exosome CDMO Market Size (2019-2030)
7.2 Europe Exosome CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Exosome CDMO Market Size by Country (2019-2024)
7.4 Europe Exosome CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Exosome CDMO Market Size (2019-2030)
8.2 Asia-Pacific Exosome CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Exosome CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Exosome CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Exosome CDMO Market Size (2019-2030)
9.2 Latin America Exosome CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Exosome CDMO Market Size by Country (2019-2024)
9.4 Latin America Exosome CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Exosome CDMO Market Size (2019-2030)
10.2 Middle East & Africa Exosome CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Exosome CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Exosome CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 REPROCELL
11.1.1 REPROCELL Company Detail
11.1.2 REPROCELL Business Overview
11.1.3 REPROCELL Exosome CDMO Introduction
11.1.4 REPROCELL Revenue in Exosome CDMO Business (2019-2024)
11.1.5 REPROCELL Recent Development
11.2 Histocell
11.2.1 Histocell Company Detail
11.2.2 Histocell Business Overview
11.2.3 Histocell Exosome CDMO Introduction
11.2.4 Histocell Revenue in Exosome CDMO Business (2019-2024)
11.2.5 Histocell Recent Development
11.3 Lonza
11.3.1 Lonza Company Detail
11.3.2 Lonza Business Overview
11.3.3 Lonza Exosome CDMO Introduction
11.3.4 Lonza Revenue in Exosome CDMO Business (2019-2024)
11.3.5 Lonza Recent Development
11.4 CytoNiche
11.4.1 CytoNiche Company Detail
11.4.2 CytoNiche Business Overview
11.4.3 CytoNiche Exosome CDMO Introduction
11.4.4 CytoNiche Revenue in Exosome CDMO Business (2019-2024)
11.4.5 CytoNiche Recent Development
11.5 MYCENAX
11.5.1 MYCENAX Company Detail
11.5.2 MYCENAX Business Overview
11.5.3 MYCENAX Exosome CDMO Introduction
11.5.4 MYCENAX Revenue in Exosome CDMO Business (2019-2024)
11.5.5 MYCENAX Recent Development
11.6 RoosterBio
11.6.1 RoosterBio Company Detail
11.6.2 RoosterBio Business Overview
11.6.3 RoosterBio Exosome CDMO Introduction
11.6.4 RoosterBio Revenue in Exosome CDMO Business (2019-2024)
11.6.5 RoosterBio Recent Development
11.7 WuXi Advanced Therapies
11.7.1 WuXi Advanced Therapies Company Detail
11.7.2 WuXi Advanced Therapies Business Overview
11.7.3 WuXi Advanced Therapies Exosome CDMO Introduction
11.7.4 WuXi Advanced Therapies Revenue in Exosome CDMO Business (2019-2024)
11.7.5 WuXi Advanced Therapies Recent Development
11.8 Asahi Glass Co.
11.8.1 Asahi Glass Co. Company Detail
11.8.2 Asahi Glass Co. Business Overview
11.8.3 Asahi Glass Co. Exosome CDMO Introduction
11.8.4 Asahi Glass Co. Revenue in Exosome CDMO Business (2019-2024)
11.8.5 Asahi Glass Co. Recent Development
11.9 Fortis Life Sciences
11.9.1 Fortis Life Sciences Company Detail
11.9.2 Fortis Life Sciences Business Overview
11.9.3 Fortis Life Sciences Exosome CDMO Introduction
11.9.4 Fortis Life Sciences Revenue in Exosome CDMO Business (2019-2024)
11.9.5 Fortis Life Sciences Recent Development
11.10 Scorpius BioManufacturing
11.10.1 Scorpius BioManufacturing Company Detail
11.10.2 Scorpius BioManufacturing Business Overview
11.10.3 Scorpius BioManufacturing Exosome CDMO Introduction
11.10.4 Scorpius BioManufacturing Revenue in Exosome CDMO Business (2019-2024)
11.10.5 Scorpius BioManufacturing Recent Development
11.11 Miltenyi Bioindustry
11.11.1 Miltenyi Bioindustry Company Detail
11.11.2 Miltenyi Bioindustry Business Overview
11.11.3 Miltenyi Bioindustry Exosome CDMO Introduction
11.11.4 Miltenyi Bioindustry Revenue in Exosome CDMO Business (2019-2024)
11.11.5 Miltenyi Bioindustry Recent Development
11.12 AGC Biologics
11.12.1 AGC Biologics Company Detail
11.12.2 AGC Biologics Business Overview
11.12.3 AGC Biologics Exosome CDMO Introduction
11.12.4 AGC Biologics Revenue in Exosome CDMO Business (2019-2024)
11.12.5 AGC Biologics Recent Development
11.13 Exothera
11.13.1 Exothera Company Detail
11.13.2 Exothera Business Overview
11.13.3 Exothera Exosome CDMO Introduction
11.13.4 Exothera Revenue in Exosome CDMO Business (2019-2024)
11.13.5 Exothera Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Exosome CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Preclinical CRO
Table 3. Key Players of Clinical CRO
Table 4. Global Exosome CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Exosome CDMO Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Exosome CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Exosome CDMO Market Share by Region (2019-2024)
Table 8. Global Exosome CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Exosome CDMO Market Share by Region (2025-2030)
Table 10. Exosome CDMO Market Trends
Table 11. Exosome CDMO Market Drivers
Table 12. Exosome CDMO Market Challenges
Table 13. Exosome CDMO Market Restraints
Table 14. Global Exosome CDMO Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Exosome CDMO Market Share by Players (2019-2024)
Table 16. Global Top Exosome CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Exosome CDMO as of 2023)
Table 17. Ranking of Global Top Exosome CDMO Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Exosome CDMO Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Exosome CDMO Product Solution and Service
Table 21. Date of Enter into Exosome CDMO Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Exosome CDMO Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Exosome CDMO Revenue Market Share by Type (2019-2024)
Table 25. Global Exosome CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Exosome CDMO Revenue Market Share by Type (2025-2030)
Table 27. Global Exosome CDMO Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Exosome CDMO Revenue Market Share by Application (2019-2024)
Table 29. Global Exosome CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Exosome CDMO Revenue Market Share by Application (2025-2030)
Table 31. North America Exosome CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Exosome CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Exosome CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Exosome CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Exosome CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Exosome CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Exosome CDMO Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Exosome CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Exosome CDMO Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Exosome CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Exosome CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Exosome CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Exosome CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Exosome CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Exosome CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 46. REPROCELL Company Detail
Table 47. REPROCELL Business Overview
Table 48. REPROCELL Exosome CDMO Product
Table 49. REPROCELL Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 50. REPROCELL Recent Development
Table 51. Histocell Company Detail
Table 52. Histocell Business Overview
Table 53. Histocell Exosome CDMO Product
Table 54. Histocell Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 55. Histocell Recent Development
Table 56. Lonza Company Detail
Table 57. Lonza Business Overview
Table 58. Lonza Exosome CDMO Product
Table 59. Lonza Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 60. Lonza Recent Development
Table 61. CytoNiche Company Detail
Table 62. CytoNiche Business Overview
Table 63. CytoNiche Exosome CDMO Product
Table 64. CytoNiche Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 65. CytoNiche Recent Development
Table 66. MYCENAX Company Detail
Table 67. MYCENAX Business Overview
Table 68. MYCENAX Exosome CDMO Product
Table 69. MYCENAX Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 70. MYCENAX Recent Development
Table 71. RoosterBio Company Detail
Table 72. RoosterBio Business Overview
Table 73. RoosterBio Exosome CDMO Product
Table 74. RoosterBio Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 75. RoosterBio Recent Development
Table 76. WuXi Advanced Therapies Company Detail
Table 77. WuXi Advanced Therapies Business Overview
Table 78. WuXi Advanced Therapies Exosome CDMO Product
Table 79. WuXi Advanced Therapies Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 80. WuXi Advanced Therapies Recent Development
Table 81. Asahi Glass Co. Company Detail
Table 82. Asahi Glass Co. Business Overview
Table 83. Asahi Glass Co. Exosome CDMO Product
Table 84. Asahi Glass Co. Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 85. Asahi Glass Co. Recent Development
Table 86. Fortis Life Sciences Company Detail
Table 87. Fortis Life Sciences Business Overview
Table 88. Fortis Life Sciences Exosome CDMO Product
Table 89. Fortis Life Sciences Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 90. Fortis Life Sciences Recent Development
Table 91. Scorpius BioManufacturing Company Detail
Table 92. Scorpius BioManufacturing Business Overview
Table 93. Scorpius BioManufacturing Exosome CDMO Product
Table 94. Scorpius BioManufacturing Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 95. Scorpius BioManufacturing Recent Development
Table 96. Miltenyi Bioindustry Company Detail
Table 97. Miltenyi Bioindustry Business Overview
Table 98. Miltenyi Bioindustry Exosome CDMO Product
Table 99. Miltenyi Bioindustry Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 100. Miltenyi Bioindustry Recent Development
Table 101. AGC Biologics Company Detail
Table 102. AGC Biologics Business Overview
Table 103. AGC Biologics Exosome CDMO Product
Table 104. AGC Biologics Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 105. AGC Biologics Recent Development
Table 106. Exothera Company Detail
Table 107. Exothera Business Overview
Table 108. Exothera Exosome CDMO Product
Table 109. Exothera Revenue in Exosome CDMO Business (2019-2024) & (US$ Million)
Table 110. Exothera Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Exosome CDMO Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Exosome CDMO Market Share by Type: 2023 VS 2030
Figure 3. Preclinical CRO Features
Figure 4. Clinical CRO Features
Figure 5. Global Exosome CDMO Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Exosome CDMO Market Share by Application: 2023 VS 2030
Figure 7. Laboratory Case Studies
Figure 8. Universities Case Studies
Figure 9. Bio Industry Case Studies
Figure 10. Medical Industry Case Studies
Figure 11. Exosome CDMO Report Years Considered
Figure 12. Global Exosome CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Exosome CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Exosome CDMO Market Share by Region: 2023 VS 2030
Figure 15. Global Exosome CDMO Market Share by Players in 2023
Figure 16. Global Top Exosome CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Exosome CDMO as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Exosome CDMO Revenue in 2023
Figure 18. North America Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Exosome CDMO Market Share by Country (2019-2030)
Figure 20. United States Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Exosome CDMO Market Share by Country (2019-2030)
Figure 24. Germany Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Exosome CDMO Market Share by Region (2019-2030)
Figure 32. China Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Exosome CDMO Market Share by Country (2019-2030)
Figure 40. Mexico Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Exosome CDMO Market Share by Country (2019-2030)
Figure 44. Turkey Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Exosome CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. REPROCELL Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 47. Histocell Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 48. Lonza Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 49. CytoNiche Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 50. MYCENAX Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 51. RoosterBio Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 52. WuXi Advanced Therapies Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 53. Asahi Glass Co. Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 54. Fortis Life Sciences Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 55. Scorpius BioManufacturing Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 56. Miltenyi Bioindustry Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 57. AGC Biologics Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 58. Exothera Revenue Growth Rate in Exosome CDMO Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
